Anti-VEGF AAV2 injections: The fewer the better

Affiliations

Comment

Leah C Byrne. Sci Transl Med. 2017.

. 2017 Jun 7;9(393):eaan4921.

doi: 10.1126/scitranslmed.aan4921.

¹ Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Email: lbyrne@pitt.edu.

Abstract

A single intravitreal injection of AAV2 provides sustained delivery of anti-VEGF protein for the treatment of neovascular AMD.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.
Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Heier JS, et al. Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Lancet. 2017. PMID: 28526489 Clinical Trial.